ATP9B
gene geneOn this page
Also known as ATPIIB
Summary
ATP9B (ATPase phospholipid transporting 9B, HGNC:13541) is a protein-coding gene on chromosome 18q23, encoding Probable phospholipid-transporting ATPase IIB (O43861).
Predicted to enable ATPase-coupled intramembrane lipid carrier activity. Predicted to be involved in endocytosis; phospholipid translocation; and retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum. Located in perinuclear region of cytoplasm and trans-Golgi network.
Source: NCBI Gene 374868 — automated summary from GO annotations (Alliance of Genome Resources).
At a glance
- GWAS associations: 5
- Clinical variants (ClinVar): 252 total — 4 pathogenic
- GTEx eGene: eQTL in 19 tissues, sQTL in 23 (q < 0.05)
- Constraint (gnomAD): pLI 0.00 (LoF-tolerant), LOEUF 0.86 (unconstrained)
- MANE Select transcript:
NM_198531 - Notable: 252 clinical variants but no curated precision-oncology (CIViC) evidence yet
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:13541 |
| Approved symbol | ATP9B |
| Name | ATPase phospholipid transporting 9B |
| Location | 18q23 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | ATPIIB |
| Ensembl gene | ENSG00000166377 |
| Ensembl biotype | protein_coding |
| OMIM | 614446 |
| Entrez | 374868 |
Gene structure
Transcript identifiers
Ensembl transcripts: 61 — 30 protein_coding, 19 nonsense_mediated_decay, 9 retained_intron, 3 protein_coding_CDS_not_defined
MANE Select: ENST00000426216
Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 4, TSL 2: 4, TSL 3: 9, TSL 4: 5, TSL 5: 3
ENST00000426216, ENST00000307671, ENST00000490210, ENST00000585674, ENST00000586366, ENST00000586672, ENST00000586722, ENST00000586774, ENST00000587410, ENST00000587878, ENST00000587919, ENST00000588600, ENST00000588772, ENST00000588895, ENST00000588921, ENST00000589326, ENST00000589732, ENST00000589951, ENST00000590163, ENST00000590271, ENST00000590477, ENST00000590608, ENST00000591395, ENST00000591464, ENST00000591518, ENST00000899989, ENST00000899990, ENST00000899991, ENST00000899992, ENST00000899993, ENST00000899994, ENST00000899995, ENST00000940834, ENST00000940835, ENST00000940836, ENST00000963364, ENST00000963365, ENST00000963366, ENST00000963367, ENST00000963368, ENST00000963369, ENST00000963370, ENST00000981934, ENST00001041112, ENST00001041113, ENST00001041114, ENST00001041115, ENST00001041116, ENST00001041117, ENST00001041118, ENST00001041119, ENST00001041120, ENST00001041121, ENST00001041122, ENST00001111071, ENST00001111072, ENST00001111073, ENST00001112228, ENST00001124528, ENST00001124529, ENST00001131526
RefSeq mRNA: 2 — MANE Select: NM_198531
NM_001306085, NM_198531
CCDS: CCDS12014, CCDS77202
Canonical transcript exons
ENST00000426216 — 30 exons
| Exon | Start | End |
|---|---|---|
| ENSE00002804876 | 79069394 | 79069529 |
| ENSE00002907374 | 79377247 | 79378283 |
| ENSE00003460183 | 79113241 | 79113354 |
| ENSE00003500111 | 79110355 | 79110505 |
| ENSE00003512812 | 79345775 | 79345839 |
| ENSE00003522135 | 79347770 | 79347925 |
| ENSE00003542338 | 79342268 | 79342366 |
| ENSE00003566056 | 79345428 | 79345572 |
| ENSE00003566891 | 79359354 | 79359462 |
| ENSE00003573559 | 79126267 | 79126375 |
| ENSE00003582657 | 79344265 | 79344354 |
| ENSE00003586322 | 79306986 | 79307234 |
| ENSE00003588591 | 79372825 | 79372882 |
| ENSE00003605429 | 79213962 | 79214038 |
| ENSE00003606422 | 79154504 | 79154555 |
| ENSE00003608960 | 79329141 | 79329302 |
| ENSE00003626646 | 79176813 | 79176907 |
| ENSE00003632982 | 79375394 | 79375426 |
| ENSE00003637813 | 79143802 | 79143860 |
| ENSE00003642337 | 79337279 | 79337449 |
| ENSE00003648208 | 79253381 | 79253541 |
| ENSE00003649880 | 79096476 | 79096649 |
| ENSE00003651762 | 79330012 | 79330104 |
| ENSE00003659061 | 79277054 | 79277196 |
| ENSE00003659967 | 79336628 | 79336711 |
| ENSE00003661910 | 79193183 | 79193263 |
| ENSE00003664371 | 79303604 | 79303716 |
| ENSE00003676250 | 79348132 | 79348196 |
| ENSE00003677118 | 79373898 | 79374101 |
| ENSE00003683253 | 79206937 | 79207012 |
Expression profiles
Bgee: expression breadth ubiquitous, 263 present calls, max score 95.09.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 15.2445 / max 178.7572, expressed in 1801 samples.
Highest expression (Bgee): sural nerve, male germ line stem cell (sensu Vertebrata) in testis, colonic epithelium, calcaneal tendon, ventricular zone.
Genetic regulation across tissues (GTEx eQTL / sQTL)
ATP9B is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 19 tissues and its splicing (sQTL) in 23 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.
showing 20 of 42 significant tissue × QTL associations:
| Tissue | QTL | q-value | Slope | Lead variant |
|---|---|---|---|---|
| Whole Blood | eqtl | 5.9e-50 | +0.50 | 18:79077760:A:G |
| Testis | sqtl | 1.5e-16 | +0.89 | 18:79139804:C:T |
| Muscle Skeletal | eqtl | 3.5e-14 | -0.30 | 18:79147989:G:T |
| Adipose Subcutaneous | sqtl | 8.8e-12 | +0.47 | 18:79261380:A:G |
| Skin Sun Exposed Lower leg | sqtl | 1.1e-10 | +0.33 | 18:79385379:G:A |
| Spleen | eqtl | 1.2e-10 | +0.38 | 18:79059843:T:A |
| Cells EBV-transformed lymphocytes | eqtl | 5.1e-10 | +0.60 | 18:79061767:T:C |
| Artery Tibial | sqtl | 3.7e-08 | +0.48 | 18:79368978:A:AC |
| Breast Mammary Tissue | sqtl | 5.5e-08 | +0.51 | 18:79261380:A:G |
| Lung | eqtl | 2.8e-07 | -0.22 | 18:79098457:T:G |
| Colon Sigmoid | sqtl | 4.5e-07 | +0.52 | 18:79375472:A:G |
| Thyroid | sqtl | 4.9e-07 | -0.40 | 18:79352916:A:C |
| Esophagus Muscularis | sqtl | 6.8e-07 | +0.45 | 18:79349150:G:A |
| Brain Frontal Cortex BA9 | eqtl | 7.0e-07 | +0.33 | 18:79330526:C:G |
| Cells Cultured fibroblasts | sqtl | 1.4e-06 | -0.57 | 18:79224827:C:T |
| Esophagus Gastroesophageal Junction | sqtl | 1.5e-06 | +0.51 | 18:79330526:C:G |
| Testis | eqtl | 2.3e-06 | -0.37 | 18:79031667:T:G |
| Nerve Tibial | eqtl | 9.8e-06 | +0.18 | 18:79100059:G:A |
| Lung | sqtl | 1.4e-05 | +0.39 | 18:79261380:A:G |
| Esophagus Mucosa | sqtl | 1.9e-05 | -0.48 | 18:79259645:C:A |
FANTOM5 promoters
7 alternative TSS:
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 170890 | 12.8133 | 1793 |
| 170891 | 1.5245 | 597 |
| 170889 | 0.6003 | 252 |
| 208611 | 0.1777 | 76 |
| 170897 | 0.0646 | 28 |
| 170898 | 0.0407 | 18 |
| 170896 | 0.0234 | 5 |
Top tissues by expression
showing 100 of 288 tissues by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| sural nerve | UBERON:0015488 | 95.09 | gold quality |
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 93.79 | gold quality |
| colonic epithelium | UBERON:0000397 | 93.38 | gold quality |
| calcaneal tendon | UBERON:0003701 | 93.06 | gold quality |
| ventricular zone | UBERON:0003053 | 91.52 | gold quality |
| adrenal tissue | UBERON:0018303 | 90.74 | gold quality |
| right testis | UBERON:0004534 | 90.53 | gold quality |
| left testis | UBERON:0004533 | 90.48 | gold quality |
| testis | UBERON:0000473 | 89.79 | gold quality |
| C1 segment of cervical spinal cord | UBERON:0006469 | 88.91 | gold quality |
| left ovary | UBERON:0002119 | 88.53 | gold quality |
| primordial germ cell in gonad | CL:0000670 ∩ UBERON:0000991 | 88.35 | gold quality |
| ectocervix | UBERON:0012249 | 88.27 | gold quality |
| tibial nerve | UBERON:0001323 | 88.07 | gold quality |
| right ovary | UBERON:0002118 | 87.97 | gold quality |
| ganglionic eminence | UBERON:0004023 | 87.87 | gold quality |
| cervix squamous epithelium | UBERON:0006922 | 87.77 | silver quality |
| lower esophagus mucosa | UBERON:0035834 | 87.73 | gold quality |
| stromal cell of endometrium | CL:0002255 | 87.62 | gold quality |
| ovary | UBERON:0000992 | 87.57 | gold quality |
| endocervix | UBERON:0000458 | 87.45 | gold quality |
| right uterine tube | UBERON:0001302 | 87.29 | gold quality |
| skin of leg | UBERON:0001511 | 87.03 | gold quality |
| stomach | UBERON:0000945 | 86.71 | gold quality |
| body of stomach | UBERON:0001161 | 86.67 | gold quality |
| skin of abdomen | UBERON:0001416 | 86.52 | gold quality |
| mucosa of transverse colon | UBERON:0004991 | 86.45 | gold quality |
| body of uterus | UBERON:0009853 | 86.45 | gold quality |
| hindlimb stylopod muscle | UBERON:0004252 | 86.42 | gold quality |
| spinal cord | UBERON:0002240 | 86.32 | gold quality |
| vagina | UBERON:0000996 | 86.19 | gold quality |
| right frontal lobe | UBERON:0002810 | 86.14 | gold quality |
| left lobe of thyroid gland | UBERON:0001120 | 86.12 | gold quality |
| popliteal artery | UBERON:0002250 | 86.08 | gold quality |
| tibial artery | UBERON:0007610 | 86.07 | gold quality |
| endothelial cell | CL:0000115 | 86.02 | gold quality |
| thyroid gland | UBERON:0002046 | 85.96 | gold quality |
| right lobe of thyroid gland | UBERON:0001119 | 85.93 | gold quality |
| left uterine tube | UBERON:0001303 | 85.81 | gold quality |
| adenohypophysis | UBERON:0002196 | 85.54 | gold quality |
| upper lobe of left lung | UBERON:0008952 | 85.44 | gold quality |
| gastrocnemius | UBERON:0001388 | 85.31 | gold quality |
| minor salivary gland | UBERON:0001830 | 85.27 | gold quality |
| muscle of leg | UBERON:0001383 | 85.18 | gold quality |
| zone of skin | UBERON:0000014 | 85.12 | gold quality |
| esophagogastric junction muscularis propria | UBERON:0035841 | 85.04 | gold quality |
| aorta | UBERON:0000947 | 84.94 | gold quality |
| tonsil | UBERON:0002372 | 84.93 | gold quality |
| bone marrow cell | CL:0002092 | 84.71 | gold quality |
| upper lobe of lung | UBERON:0008948 | 84.69 | gold quality |
| muscle layer of sigmoid colon | UBERON:0035805 | 84.66 | gold quality |
| blood | UBERON:0000178 | 84.55 | gold quality |
| monocyte | CL:0000576 | 84.52 | gold quality |
| germinal epithelium of ovary | UBERON:0001304 | 84.50 | silver quality |
| prefrontal cortex | UBERON:0000451 | 84.49 | gold quality |
| adrenal gland | UBERON:0002369 | 84.47 | gold quality |
| lower esophagus muscularis layer | UBERON:0035833 | 84.42 | gold quality |
| lower esophagus | UBERON:0013473 | 84.41 | gold quality |
| right hemisphere of cerebellum | UBERON:0014890 | 84.38 | gold quality |
| mononuclear cell | CL:0000842 | 84.37 | gold quality |
| CA1 field of hippocampus | UBERON:0003881 | 84.36 | silver quality |
| leukocyte | CL:0000738 | 84.30 | gold quality |
| cortical plate | UBERON:0005343 | 84.23 | gold quality |
| mucosa of stomach | UBERON:0001199 | 84.20 | gold quality |
| metanephros cortex | UBERON:0010533 | 84.16 | gold quality |
| right adrenal gland cortex | UBERON:0035827 | 84.13 | gold quality |
| right lung | UBERON:0002167 | 84.08 | gold quality |
| pituitary gland | UBERON:0000007 | 83.98 | gold quality |
| left adrenal gland cortex | UBERON:0035825 | 83.98 | gold quality |
| esophagus | UBERON:0001043 | 83.92 | gold quality |
| ascending aorta | UBERON:0001496 | 83.87 | gold quality |
| saliva-secreting gland | UBERON:0001044 | 83.80 | gold quality |
| left adrenal gland | UBERON:0001234 | 83.80 | gold quality |
| thoracic aorta | UBERON:0001515 | 83.71 | gold quality |
| cerebellar hemisphere | UBERON:0002245 | 83.70 | gold quality |
| cerebellar cortex | UBERON:0002129 | 83.61 | gold quality |
| mouth mucosa | UBERON:0003729 | 83.60 | gold quality |
| right adrenal gland | UBERON:0001233 | 83.59 | gold quality |
| primary visual cortex | UBERON:0002436 | 83.55 | gold quality |
| granulocyte | CL:0000094 | 83.53 | gold quality |
| Brodmann (1909) area 23 | UBERON:0013554 | 83.50 | gold quality |
| corpus callosum | UBERON:0002336 | 83.36 | gold quality |
| left coronary artery | UBERON:0001626 | 83.35 | gold quality |
| prostate gland | UBERON:0002367 | 83.34 | gold quality |
| esophagus mucosa | UBERON:0002469 | 83.34 | gold quality |
| subcutaneous adipose tissue | UBERON:0002190 | 83.20 | gold quality |
| transverse colon | UBERON:0001157 | 83.18 | gold quality |
| descending thoracic aorta | UBERON:0002345 | 83.17 | gold quality |
| right atrium auricular region | UBERON:0006631 | 83.15 | gold quality |
| right coronary artery | UBERON:0001625 | 83.06 | gold quality |
| body of pancreas | UBERON:0001150 | 83.04 | gold quality |
| omental fat pad | UBERON:0010414 | 82.92 | gold quality |
| Brodmann (1909) area 9 | UBERON:0013540 | 82.91 | gold quality |
| right lobe of liver | UBERON:0001114 | 82.87 | gold quality |
| peritoneum | UBERON:0002358 | 82.85 | gold quality |
| tendon | UBERON:0000043 | 82.81 | gold quality |
| adrenal cortex | UBERON:0001235 | 82.67 | gold quality |
| small intestine Peyer’s patch | UBERON:0003454 | 82.55 | gold quality |
| cingulate cortex | UBERON:0003027 | 82.53 | gold quality |
| adipose tissue of abdominal region | UBERON:0007808 | 82.52 | gold quality |
Single-cell (SCXA)
Detected in 6 experiment(s), a significant marker in 1.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-ANND-3 | yes | 6.11 |
| E-CURD-135 | no | 2928.00 |
| E-HCAD-6 | no | 448.08 |
| E-HCAD-8 | no | 442.67 |
| E-MTAB-7249 | no | 271.29 |
| E-GEOD-137537 | no | 5.64 |
HPA expression
RNA tissue specificity: Low tissue specificity
showing 60 of 80 HPA tissues / cells by nTPM:
| Tissue / cell | Axis | nTPM | Protein (IHC) |
|---|---|---|---|
| Postcentral gyrus | tissue | 154.9 | |
| Choroid plexus | tissue | 141.6 | |
| Hippocampus | tissue | 140.1 | low |
| Nucleus accumbens | tissue | 136.2 | |
| Locus coeruleus | tissue | 115.3 | |
| Corpus callosum | tissue | 34.4 | |
| Periaqueductal gray | tissue | 33.9 | |
| Spinal cord | tissue | 31.9 | |
| Midbrain | tissue | 29.2 | |
| Medulla oblongata | tissue | 29.2 | |
| Bone marrow | tissue | 28.3 | medium |
| Pons | tissue | 27.9 | |
| Hypothalamus | tissue | 27.9 | |
| Thalamus | tissue | 27.6 | |
| Substantia nigra | tissue | 27.0 | |
| Hippocampal formation | tissue | 25.5 | |
| Superior colliculi | tissue | 25.1 | |
| Septum | tissue | 24.6 | |
| Cerebral cortex | tissue | 23.9 | medium |
| Motor cortex | tissue | 23.9 | |
| Amygdala | tissue | 23.3 | |
| Ventral forebrain | tissue | 23.3 | |
| Basal ganglia | tissue | 23.2 | low |
| Somatosensory cortex | tissue | 23.2 | |
| Prefrontal cortex | tissue | 23.1 | |
| Entorhinal cortex | tissue | 23.1 | |
| Putamen | tissue | 22.7 | |
| Retrosplenial cortex | tissue | 22.4 | |
| Temporal cortex | tissue | 21.9 | |
| Occipital cortex | tissue | 21.9 | |
| Retrosplenial and cingulate cortex | tissue | 21.8 | |
| Insular cortex | tissue | 21.7 | |
| Cerebellum | tissue | 20.6 | low |
| Olfactory bulb | tissue | 20.3 | |
| Retina | tissue | 17.5 | |
| Testis | tissue | 16.8 | medium |
| Caudate putamen | tissue | 15.3 | |
| Parathyroid gland | tissue | 13.3 | low |
| Liver | tissue | 13.2 | not detected |
| Frontal cortex | tissue | 13.1 | |
| Thyroid gland | tissue | 10.8 | high |
| Skin 1 | tissue | 10.3 | medium |
| Endometrium 1 | tissue | 9.9 | medium |
| Prostate | tissue | 9.6 | low |
| Stomach 1 | tissue | 9.5 | not detected |
| Ovary | tissue | 9.5 | not detected |
| Salivary gland | tissue | 9.5 | medium |
| Kidney | tissue | 9.4 | medium |
| Lung | tissue | 9.2 | medium |
| Skeletal muscle | tissue | 9.1 | medium |
| Esophagus | tissue | 8.8 | medium |
| Pancreas | tissue | 8.8 | medium |
| Lymph node | tissue | 8.5 | low |
| Thymus | tissue | 8.5 | |
| Epididymis | tissue | 8.4 | medium |
| Fallopian tube | tissue | 8.4 | medium |
| Placenta | tissue | 8.3 | high |
| Rectum | tissue | 8.1 | medium |
| Breast | tissue | 8.0 | medium |
| Spleen | tissue | 7.9 | low |
Brain sub-regions (HPA Brain Atlas): detected in 192; highest nTPM — Somatosensory cortex, postcentral gyrus, ventral (white matter) (185.1), Flocculonodular lobe (181.2), Vermis (179.7), Parieto-temporal junction (white matter) (174.3), Cerebellar cortex (172.3).
Regulation
Is transcription factor: no
Upstream regulators (CollecTRI, top): CTNNBL1, MYB, MYF5, MYOD1, SPI1
miRNA regulators (miRDB)
Targeting ATP9B by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).
showing 30 of 61 miRNAs:
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-4510 | 100.00 | 66.60 | 2050 |
| HSA-MIR-6127 | 100.00 | 66.76 | 2188 |
| HSA-MIR-6129 | 100.00 | 66.46 | 2080 |
| HSA-MIR-6130 | 100.00 | 66.69 | 2012 |
| HSA-MIR-6133 | 100.00 | 66.48 | 2064 |
| HSA-MIR-3120-5P | 100.00 | 65.56 | 965 |
| HSA-MIR-3688-3P | 99.97 | 72.02 | 2834 |
| HSA-MIR-1250-3P | 99.96 | 70.04 | 4038 |
| HSA-MIR-4666A-3P | 99.96 | 71.71 | 3434 |
| HSA-MIR-545-3P | 99.95 | 70.74 | 2783 |
| HSA-MIR-4731-5P | 99.89 | 67.23 | 2537 |
| HSA-MIR-30A-3P | 99.87 | 69.74 | 2928 |
| HSA-MIR-30D-3P | 99.87 | 69.92 | 2917 |
| HSA-MIR-30E-3P | 99.87 | 69.68 | 2942 |
| HSA-MIR-221-5P | 99.86 | 65.45 | 1052 |
| HSA-MIR-8073 | 99.86 | 65.21 | 1118 |
| HSA-MIR-378G | 99.71 | 64.90 | 1106 |
| HSA-MIR-3158-5P | 99.65 | 67.51 | 1763 |
| HSA-MIR-298 | 99.63 | 67.56 | 1916 |
| HSA-MIR-7150 | 99.62 | 66.80 | 1322 |
| HSA-MIR-1207-5P | 99.49 | 69.11 | 2983 |
| HSA-MIR-5571-5P | 99.49 | 66.99 | 1764 |
| HSA-MIR-6722-3P | 99.45 | 67.62 | 1919 |
| HSA-MIR-4427 | 99.34 | 70.33 | 1854 |
| HSA-MIR-3606-5P | 99.31 | 69.67 | 1168 |
| HSA-MIR-4292 | 99.16 | 65.57 | 1767 |
| HSA-MIR-6791-5P | 99.16 | 65.92 | 1844 |
| HSA-MIR-4763-3P | 99.10 | 67.83 | 2649 |
| HSA-MIR-661 | 99.09 | 65.94 | 2062 |
| HSA-MIR-6868-5P | 99.06 | 65.69 | 1284 |
Functional genomics
gnomAD constraint: pLI 2.77e-19, LOEUF 0.857, missense Z 0.619 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD
Regional missense constraint (gnomAD RMC): no regional variation along ENST00000426216 — one region, missense o/e 1.00.
Literature-anchored findings (GeneRIF, showing 1)
- These results revealed that human human macrophage MHC receptor 1 on monocytes is a novel receptor specific for HLA-B44. (PMID:22525042)
Cross-species orthologs
6 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | atp9b | ENSDARG00000062521 |
| mus_musculus | Atp9b | ENSMUSG00000024566 |
| rattus_norvegicus | Atp9b | ENSRNOG00000032039 |
| drosophila_melanogaster | CG31729 | FBGN0051729 |
| caenorhabditis_elegans | tat-5 | WBGENE00009498 |
| caenorhabditis_elegans | WBGENE00017174 |
Paralogs (13): ATP9A (ENSG00000054793), ATP11B (ENSG00000058063), ATP11A (ENSG00000068650), ATP8B1 (ENSG00000081923), ATP11C (ENSG00000101974), ATP8B4 (ENSG00000104043), ATP10B (ENSG00000118322), ATP8A1 (ENSG00000124406), ATP8B3 (ENSG00000130270), ATP8A2 (ENSG00000132932), ATP8B2 (ENSG00000143515), ATP10D (ENSG00000145246), ATP10A (ENSG00000206190)
Mouse-model phenotypes
Observed phenotypes of the mouse ortholog (MGI:1354757) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 2 distinct phenotype terms.
| Mouse phenotype (MP) | Records |
|---|---|
| abnormal vocalization | 1 |
| abnormal coat/hair pigmentation | 1 |
Additional cross-species homologs
Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.
| Organism | UniProt | Identity | Method |
|---|---|---|---|
| Bos taurus | Q29449 | 96.0% | Diamond |
| Macaca fascicularis | Q9GKS6 | 88.7% | Diamond |
| Arabidopsis thaliana | Q9LK90 | 64.8% | Diamond |
| Schizosaccharomyces pombe 972h- | O94296 | 59.5% | Diamond |
| Saccharomyces cerevisiae S288C | P39524 | 59.5% | Diamond |
| Toxoplasma gondii GT1 | S7VVK4 | 47.9% | Diamond |
Genomic neighbors (locus context)
Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).
| Symbol | Type | Entrez |
|---|---|---|
| SALL3 | protein-coding | 27164 |
| LINC01896 | ncRNA | 645321 |
| NFATC1 | protein-coding | 4772 |
Protein
Protein identifiers
Probable phospholipid-transporting ATPase IIB — O43861 (reviewed: O43861)
Alternative names: ATPase class II type 9B
All UniProt accessions (12): O43861, B4DJ94, K7EII3, K7EJG1, K7EJP9, K7EJS3, K7EL57, K7EPH4, K7EQ39, K7EQQ5, K7ERE0, K7ES39
UniProt curated annotations — full annotation on UniProt →
Subcellular location. Golgi apparatus. trans-Golgi network membrane.
Similarity. Belongs to the cation transport ATPase (P-type) (TC 3.A.3) family. Type IV subfamily.
Isoforms (2)
| UniProt ID | Names | Canonical? |
|---|---|---|
| O43861-1 | 1 | yes |
| O43861-2 | 2 |
RefSeq proteins (2): NP_001293014, NP_940933* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR001757 | P_typ_ATPase | Family |
| IPR006539 | P-type_ATPase_IV | Family |
| IPR008250 | ATPase_P-typ_transduc_dom_A_sf | Homologous_superfamily |
| IPR018303 | ATPase_P-typ_P_site | PTM |
| IPR023214 | HAD_sf | Homologous_superfamily |
| IPR023298 | ATPase_P-typ_TM_dom_sf | Homologous_superfamily |
| IPR023299 | ATPase_P-typ_cyto_dom_N | Homologous_superfamily |
| IPR032630 | P_typ_ATPase_c | Domain |
| IPR032631 | P-type_ATPase_N | Domain |
| IPR036412 | HAD-like_sf | Homologous_superfamily |
| IPR044492 | P_typ_ATPase_HD_dom | Domain |
| IPR059000 | ATPase_P-type_domA | Domain |
Pfam: PF00122, PF00702, PF16209, PF16212
UniProt features (58 total): binding site 20, topological domain 11, transmembrane region 10, sequence conflict 8, sequence variant 4, chain 1, region of interest 1, compositionally biased region 1, active site 1, splice variant 1
Structure
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-O43861-F1 | 79.49 | 0.29 |
Human Protein Atlas
Protein class: Enzymes, ENZYME proteins, Predicted membrane proteins, Predicted intracellular proteins, UniProt - Evidence at transcript level
Protein evidence: Evidence at protein level
Antibody reliability (HPA): IH approved
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Catalytic / active sites (1)
| Position | Role |
|---|---|
| 468 | 4-aspartylphosphate intermediate |
Ligand- & substrate-binding residues (20)
| Position | Role |
|---|---|
| 468 | ATP |
| 468 | Mg(2+) |
| 469 | ATP |
| 470 | ATP |
| 470 | Mg(2+) |
| 591 | ATP |
| 633 | ATP |
| 638 | ATP |
| 657 | ATP |
| 686 | ATP |
| 687 | ATP |
| 766 | ATP |
| 767 | ATP |
| 768 | ATP |
| 848 | ATP |
| 854 | ATP |
| 874 | Mg(2+) |
| 877 | ATP |
| 878 | ATP |
| 878 | Mg(2+) |
Function
Pathways and Gene Ontology
Reactome pathways
1 curated (TAS) of 3; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).
3 pathways:
| ID | Pathway | Evidence |
|---|---|---|
| R-HSA-936837 | Ion transport by P-type ATPases | curated |
| R-HSA-983712 | Ion channel transport | — |
| R-HSA-382551 | Transport of small molecules | — |
MSigDB gene sets: 145 (showing top):
IVANOVA_HEMATOPOIESIS_LATE_PROGENITOR, GOBP_VESICLE_MEDIATED_TRANSPORT, GOBP_REGULATION_OF_MEMBRANE_LIPID_DISTRIBUTION, GOBP_ORGANOPHOSPHATE_ESTER_TRANSPORT, GOCC_TRANS_GOLGI_NETWORK, RUTELLA_RESPONSE_TO_CSF2RB_AND_IL4_UP, FOSTER_TOLERANT_MACROPHAGE_UP, WANG_CISPLATIN_RESPONSE_AND_XPC_DN, GOBP_PHOSPHOLIPID_TRANSPORT, GOBP_MEMBRANE_ORGANIZATION, GRYDER_PAX3FOXO1_ENHANCERS_IN_TADS, GOBP_IMPORT_INTO_CELL, GOBP_LIPID_LOCALIZATION, GOBP_ENDOCYTOSIS, GRYDER_PAX3FOXO1_TOP_ENHANCERS
GO Biological Process (5): retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum (GO:0006890), endocytosis (GO:0006897), phospholipid translocation (GO:0045332), lipid transport (GO:0006869), phospholipid transport (GO:0015914)
GO Molecular Function (7): magnesium ion binding (GO:0000287), ATP binding (GO:0005524), ATP hydrolysis activity (GO:0016887), ATPase-coupled intramembrane lipid carrier activity (GO:0140326), nucleotide binding (GO:0000166), transporter activity (GO:0005215), metal ion binding (GO:0046872)
GO Cellular Component (7): endosome (GO:0005768), trans-Golgi network (GO:0005802), plasma membrane (GO:0005886), perinuclear region of cytoplasm (GO:0048471), Golgi apparatus (GO:0005794), endomembrane system (GO:0012505), membrane (GO:0016020)
Reactome top-level categories
2 top-level categories:
| Category | Pathways |
|---|---|
| Ion channel transport | 1 |
| Transport of small molecules | 1 |
GO top-level categories
31 GO namespaces:
| Category | Terms |
|---|---|
| cellular anatomical structure | 3 |
| ATP-dependent activity | 2 |
| endomembrane system | 2 |
| cytoplasm | 2 |
| Golgi vesicle transport | 1 |
| vesicle budding from membrane | 1 |
| membrane invagination | 1 |
| import into cell | 1 |
| phospholipid transport | 1 |
| lipid translocation | 1 |
| transport | 1 |
| lipid localization | 1 |
| lipid transport | 1 |
| organophosphate ester transport | 1 |
| metal ion binding | 1 |
| adenyl ribonucleotide binding | 1 |
| purine ribonucleoside triphosphate binding | 1 |
| anion binding | 1 |
| ribonucleoside triphosphate phosphatase activity | 1 |
| intramembrane lipid carrier activity | 1 |
| nucleoside phosphate binding | 1 |
| heterocyclic compound binding | 1 |
| molecular_function | 1 |
| cation binding | 1 |
| cytoplasmic vesicle | 1 |
| Golgi apparatus subcompartment | 1 |
| membrane | 1 |
| cell periphery | 1 |
| intracellular membrane-bounded organelle | 1 |
| vacuole | 1 |
| plasma membrane | 1 |
Experimentally-supported GO annotations
GO terms backed by direct experimental evidence (ECO experimental codes) — 2 of 19 annotations. The rest are phylogenetic / computational / electronic (IEA).
2 experimentally-supported GO terms:
| GO term | NS | Evidence |
|---|---|---|
| perinuclear region of cytoplasm | CC | direct assay |
| trans-Golgi network | CC | direct assay |
Protein interactions and networks
STRING
showing 15 of 574 interactions by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| ATP9B | CDC50A | Q9NV96 | 624 |
| ATP9B | CDC50B | Q3MIR4 | 604 |
| ATP9B | SLC66A2 | Q8N2U9 | 486 |
| ATP9B | DOP1A | Q5JWR5 | 481 |
| ATP9B | MON2 | Q7Z3U7 | 452 |
| ATP9B | NEO1 | Q92859 | 441 |
| ATP9B | DOP1B | Q9Y3R5 | 404 |
| ATP9B | KCTD20 | Q7Z5Y7 | 394 |
| ATP9B | SALL3 | Q9BXA9 | 370 |
| ATP9B | RBFA | Q8N0V3 | 365 |
| ATP9B | ZNF407 | Q9C0G0 | 357 |
| ATP9B | SMIM21 | Q3B7S5 | 357 |
| ATP9B | TXNL4A | P83876 | 356 |
| ATP9B | EVA1C | P58658 | 346 |
| ATP9B | ZNF75D | P51815 | 345 |
IntAct
Human interaction partners of ATP9B in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).
2 partners by confidence:
| Partner | Interaction type | MIscore | Records |
|---|---|---|---|
| ATP9A | association | 0.350 | 1 |
| AVPR2 | association | 0.350 | 1 |
BioGRID (24 interactions; top human partners by supporting records): ANKH (Affinity Capture-MS), ATP13A3 (Co-fractionation), ATP7B (Co-fractionation), ATP9A (Affinity Capture-MS), DDX58 (Affinity Capture-RNA), DVL2 (Affinity Capture-MS), HNRNPL (Affinity Capture-RNA), IGSF8 (Co-fractionation), KIAA1429 (Affinity Capture-RNA), MFSD5 (Affinity Capture-MS), NUDT21 (Affinity Capture-RNA), PARP3 (Proximity Label-MS), PDE2A (Affinity Capture-MS), PTK7 (Co-fractionation), SLC15A3 (Affinity Capture-MS)
Disease & clinical
Genetic variants
Variant evidence for ATP9B: 252 ClinVar records (4 pathogenic / likely pathogenic); 5 GWAS associations. Per-variant detail is on Sugi Variant.
ClinVar
252 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 4 |
| Likely pathogenic | 0 |
| Uncertain significance | 182 |
| Likely benign | 15 |
| Benign | 5 |
Top pathogenic / likely-pathogenic (4)
Showing all 4 pathogenic / likely-pathogenic ClinVar records, ranked by ClinVar review status (expert panel → multiple submitters → single submitter), then by number of submitting labs.
| Variant ID | HGVS | Classification | Review | Submitters |
|---|---|---|---|---|
| 1526633 | GRCh37/hg19 18q22.1-23(chr18:64340599-77273893)x1 | Pathogenic | criteria provided, single submitter | 1 |
| 149476 | GRCh38/hg38 18q22.3-23(chr18:72043906-80254936)x1 | Pathogenic | no assertion criteria provided | 1 |
| 242603 | NC_000018.9:g.73376178_78077248del4701071 | Pathogenic | no assertion criteria provided | 1 |
| 564566 | GRCh37/hg19 18q21.33-23(chr18:60416709-78014123)x1 | Pathogenic | no assertion criteria provided | 1 |
Per-variant reference — Sugi Variant
Explore ATP9B’s pathogenic and likely-pathogenic variants individually — each with its ClinVar classification and conditions, applied ACMG criteria (ClinGen expert panel, where curated), the calibrated in-silico predictors (AlphaMissense, REVEL, SaProt, conservation), gnomAD frequency, and the predictor-disagreement QC signal — on Sugi Variant.
SpliceAI
Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 31 predictions of 4,263):
| Position(s) | Effect | Δscore | Sites |
|---|---|---|---|
| 18:79069530–79069531 | donor_loss | 1.0000 | 2 |
| 18:79113355–79113356 | donor_loss | 1.0000 | 6 |
| 18:79126265–79126266 | acceptor_loss | 1.0000 | 2 |
| 18:79126336 | donor_gain | 1.0000 | |
| 18:79126376–79126377 | donor_loss | 1.0000 | 5 |
| 18:79206934 | acceptor_gain | 1.0000 | |
| 18:79253542–79253543 | donor_loss | 1.0000 | 3 |
| 18:79277197–79277198 | donor_loss | 1.0000 | 5 |
| 18:79303598 | acceptor_gain | 1.0000 | |
| 18:79303602–79303603 | acceptor_loss | 1.0000 | 5 |
AlphaMissense
3,334 missense substitutions predicted likely pathogenic (of 7,532 scored), across 817 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:
| Residue | Likely-pathogenic substitutions | Mean am_pathogenicity | Max am_pathogenicity |
|---|---|---|---|
| M478 | 9 | 0.986 | 0.999 |
| M640 | 9 | 0.951 | 0.992 |
| M881 | 9 | 0.924 | 0.995 |
| D468 | 8 | 0.998 | 1.000 |
| D878 | 8 | 0.998 | 0.999 |
| D590 | 8 | 0.997 | 0.999 |
| D742 | 8 | 0.996 | 0.999 |
| D768 | 8 | 0.996 | 0.999 |
| D249 | 8 | 0.992 | 0.997 |
| D208 | 8 | 0.989 | 0.998 |
| D270 | 8 | 0.989 | 0.997 |
| D874 | 8 | 0.986 | 0.997 |
| F633 | 8 | 0.985 | 0.999 |
| D904 | 8 | 0.983 | 0.994 |
| N877 | 8 | 0.977 | 0.999 |
| N476 | 8 | 0.976 | 0.995 |
| H937 | 8 | 0.976 | 0.992 |
| S588 | 8 | 0.975 | 1.000 |
| F312 | 8 | 0.974 | 0.997 |
| D429 | 8 | 0.966 | 0.994 |
HPA cancer prognostics
RNA cancer specificity: Low cancer specificity
Human Protein Atlas survival analysis — favorable = higher expression predicts better survival.
1 prognostic cancer types:
| Cancer | Prognostic | p-value |
|---|---|---|
| Kidney Renal Clear Cell Carcinoma (validation) | favorable | 0.000974 |
Disease associations
OMIM: gene MIM:614446 | disease phenotypes: MIM:608572
GenCC curated gene-disease
Mondo (1): choanal atresia-hearing loss-cardiac defects-craniofacial dysmorphism syndrome (MONDO:0012064)
Orphanet (1): Burn-McKeown syndrome (Orphanet:1200)
GWAS associations
5 associations:
| Study | Trait | p-value |
|---|---|---|
| GCST001942_18 | Prostate cancer | 2e-9 |
| GCST006148_11 | Frontotemporal dementia with GRN mutation | 1e-6 |
| GCST009391_1782 | Metabolite levels | 3e-6 |
| GCST011983_19 | Fasting glucose | 4e-6 |
| GCST006154_6 | Frontotemporal dementia | 6e-6 |
EFO canonical traits (from GWAS)
1 canonical traits:
| EFO ID | Trait name |
|---|---|
| EFO:0009792 | valine measurement |
MeSH disease descriptors
1 disease descriptors:
| Descriptor | Name | Tree numbers |
|---|---|---|
| C563682 | Oculootofacial Dysplasia *(supp.)* |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (CPIC guideline: no)
GtoPdb / IUPHAR curated pharmacology
(IUPHAR/BPS Guide to Pharmacology — expert-curated)
Target class: transporter — P4 P-type ATPases: Phospholipid-transporting ATPases
CTD chemical–gene interactions
29 total (human), top 29 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| bisphenol A | affects expression, decreases expression | 2 |
| sodium arsenite | decreases expression, increases abundance, increases expression | 2 |
| Arsenic | affects methylation, decreases expression, increases abundance | 2 |
| Benzo(a)pyrene | decreases expression | 2 |
| Aflatoxin B1 | decreases methylation, affects methylation | 2 |
| Cadmium Chloride | increases abundance, increases expression | 2 |
| methylmercuric chloride | decreases expression | 1 |
| triphenyl phosphate | affects expression | 1 |
| uranyl acetate | affects expression | 1 |
| arsenite | affects binding, decreases reaction | 1 |
| 1,6-hexamethylene diisocyanate | increases methylation | 1 |
| manganese chloride | decreases expression, increases abundance | 1 |
| aflatoxin B2 | increases methylation | 1 |
| di-n-butylphosphoric acid | affects expression | 1 |
| CGP 52608 | affects binding, increases reaction | 1 |
| bisphenol S | decreases methylation | 1 |
| Resveratrol | increases expression | 1 |
| Cadmium | increases abundance, increases expression | 1 |
| Cocaine | affects response to substance | 1 |
| Formaldehyde | decreases expression | 1 |
| Hydrogen Peroxide | increases expression | 1 |
| Manganese | decreases expression, increases abundance | 1 |
| Sarin | increases expression | 1 |
| Testosterone | decreases expression | 1 |
| Tobacco Smoke Pollution | decreases expression | 1 |
| Uranium | affects expression | 1 |
| Valproic Acid | decreases methylation | 1 |
| 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | decreases expression | 1 |
| Cyclosporine | increases methylation | 1 |
Cellosaurus cell lines
3 cell lines: 3 cancer cell line
First 10 cell lines (id-ordered, not curated):
| Cellosaurus | Name | Category | Sex |
|---|---|---|---|
| CVCL_SE22 | HAP1 ATP9B (-) 1 | Cancer cell line | Male |
| CVCL_XL79 | HAP1 ATP9B (-) 2 | Cancer cell line | Male |
| CVCL_XL80 | HAP1 ATP9B (-) 3 | Cancer cell line | Male |
Clinical trials (associated diseases)
Via MONDO — disease-level, not drug-specific.
Related Atlas pages
- Disease cohort memberships (association, not causation — diseases whose associated-gene cohort lists this gene; a subset are also under Associated diseases): frontotemporal dementia